Literature DB >> 2860356

Diphosphonates for osteolytic metastases.

I Elomaa, C Blomqvist, L Porkka, T Holmström, T Taube, C Lamberg-Allardt, G H Borgström.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2860356     DOI： 10.1016/s0140-6736(85)92455-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Treating bony metastases.

Authors:  D Dodwell; A Howell
Journal:  BMJ       Date:  1991-08-24

2.  A model of localized osteolysis induced by the MBT-2 tumor in mice and its responsiveness to etidronate disodium.

Authors:  R Nemoto; K Uchida; M Tsutsumi; K Koiso; S Satou; T Satou
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

Review 3.  The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.

Authors:  E V McCloskey; J F Guest; J A Kanis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

Review 5.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 6.  Postmenopausal breast cancer. Drug therapy in the 1990s.

Authors:  C I Falkson; G Falkson; H C Falkson
Journal:  Drugs Aging       Date:  1993 Mar-Apr       Impact factor: 3.923

7.  Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases.

Authors:  A Mañas; F Casas; J P Ciria; C López; J Sáez; A Palacios; M de las Heras; C Porto; E Sánchez; C Martín; R Esco; C Veiras; J C Martínez; M Márquez; A Ramos; F Calvo; J Fuertes; F J Andreu; J Contreras; L Pérez; J Romero; J Vayreda; C Victoria
Journal:  Clin Transl Oncol       Date:  2008-05       Impact factor: 3.405

8.  Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Authors:  R E Coleman; P J Woll; M Miles; W Scrivener; R D Rubens
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.